Back to Search
WHITNEY PRINCE, M.D.
M.D.
Pulmonary Disease Physician
NPI: 1265682181IndividualAccepts Medicare
Specialties, Licenses & Credentials
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
N0383(TX)
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
N0383(TX)
Education
UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
Class of 2005
Research & Publications (10)
Future challenges for microsomal transport protein inhibitors.
PMID 19601852·Curr Vasc Pharmacol·2009
6-review
Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase).
PMID 18709516·AAPS J·2008
4-observational
Prosopis juliflora--a green solution to decontaminate heavy metal (Cu and Cd) contaminated soils.
PMID 16054919·Chemosphere·2005
8-other
Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase.
PMID 15170390·J Biol Chem·2004
7-preclinical
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
PMID 12162471·J Clin Pharmacol·2002
3-trial
Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation.
PMID 11850287·Antimicrob Agents Chemother·2002
3-trial
Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
PMID 11583478·J Clin Pharmacol·2001
3-trial
The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers.
PMID 11361049·J Clin Pharmacol·2001
3-trial
Brain and CSF entry of the novel non-nucleoside reverse transcriptase inhibitor, GW420867X.
PMID 11117496·Neuroreport·2000
7-preclinical
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.
PMID 10817724·Antimicrob Agents Chemother·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2401 S 31ST ST
TEMPLE, TX 76508 - Phone
- (254) 724-2111
Quick Facts
- NPI
- 1265682181
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 21
- Publications
- 10
Are you this provider?
Claim Your Profile